Latest News

 

JavaScript findLinksAndSetTargets()
(to open ext. links in new window)

Story Highlights

An international team of scientists — led by Texan researchers — have coalesced to rapidly identify drug-like molecules that inhibit SARS-CoV-2 replication.

The COVID-19 Drug Discovery Consortium used TACC supercomputers to screen 2.6 million small molecules against all the major non-structural proteins of SARS-CoV-2 and identified the 600 most likely to be effective at disrupting the virus.

Through partnerships with Boston University, Texas A&M University, UT Medical Branch, and Enamine, the team will physically make a library of potential drug compounds and test them for efficacy and safety, leading to potential new drug leads within a month.


Contact

Faith Singer

Communications Manager
faith@tacc.utexas.edu | 512-232-5771

Aaron Dubrow

Science And Technology Writer
aarondubrow@tacc.utexas.edu

Jorge Salazar

Technical Writer/Editor
jorge@tacc.utexas.edu | 512-475-9411